Complete reference list (PDF 1191 KB) - Department of Health and ...

78. Marti F, Steffen R, Mutsch M. Influenza vaccine: a travelers‘ vaccine? Expert Review of Vaccines
2008;7:679-87.
79. Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during
pregnancy. American Journal of Obstetrics and Gynecology 2005;192:1098-106.
80. Pool V, Iskander J. Safety of influenza vaccination during pregnancy [letter]. American Journal of
Obstetrics and Gynecology 2006;194:1200.
81. Tamma PD, Ault KA, del Rio C, et al. Safety of influenza vaccination during pregnancy.
American Journal of Obstetrics and Gynecology 2009;201:547-52.
82. Greenhawt MJ, Li JT, Bernstein DI, et al. Administering influenza vaccine to egg allergic
recipients: a focused practice parameter update. Annals of Allergy, Asthma and Immunology
2011;106:11-6.
83. Mullins RJ, Gold MS. Influenza vaccination of the egg-allergic individual [letter]. Medical
Journal of Australia 2011;195:52-3.
84. Australasian Society of Clinical Immunology and Allergy (ASCIA). Guidelines for medical
practitioners: Influenza vaccination of the egg-allergic individual. 2010. Available at:
http://www.allergy.org.au/health-professionals/papers/influenza-vaccination-of-the-egg-allergicindividual
(accessed July 2011).
85. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the
administration of influenza vaccine in children allergic to egg. BMJ 2009;339:912-5.
86. Kelso JM. Administration of influenza vaccines to patients with egg allergy: update for the 2010–
2011 season [letter]. Journal of Allergy and Clinical Immunology 2010;126:1302-4.
87. Burwen DR, Ball R, Bryan WW, et al. Evaluation of Guillain-Barré Syndrome among recipients
of influenza vaccine in 2000 and 2001. American Journal of Preventive Medicine 2010;39:296-
304.
88. Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian
children aged six months to four years with trivalent inactivated seasonal influenza vaccine in
2010. Eurosurveillance 2010;15(37):pii=19661.
89. Mahajan D, Roomiani I, Gold MS, et al. Annual report: surveillance of adverse events following
immunisation in Australia, 2009. Communicable Diseases Intelligence 2010;34:259-76.
90. Mahajan D, Menzies R, Cook J, Macartney K, McIntyre P. Supplementary report: surveillance of
adverse events following immunisation among children aged less than 7 years in Australia, 1
January to 30 June 2010. Communicable Diseases Intelligence 2011;35:21-8.
91. Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in
young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ
Open 2011;1:e000016. doi:10.1136/bmjopen-2010-000016.
92. Australian Government Department of Health and Ageing, Therapeutic Goods Administration.
Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza
vaccination. 2010. Available at: http://www.tga.gov.au/pdf/alerts-medicine-seasonal-flu-
100702.pdf (accessed Sep 2012).
93. Duggan ST, Plosker GL. Intanza ® 15 μg intradermal seasonal influenza vaccine in older adults
(aged 60 years): profile report. Biodrugs 2010;24:407-9.
94. Nelson KE. Invited commentary: influenza vaccine and Guillain-Barré syndrome – is there a risk?
American Journal of Epidemiology 2012;175:1129-32.
95. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an
abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012;7:e33536.
doi:10.1371/journal.pone.0033536.
96. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy [letter]. Sleep
2010;33:1428-30.
97. Communicable Diseases Network Australia (CDNA). Influenza infection: CDNA national
guidelines for public health units. 2011. Available at: http://www.health.gov.au/cdnasongs
(accessed July 2012).